Shares of Quest Diagnostics DGX moved higher by 3% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share were up 144.89% year over year to $4.31, which beat the estimate of $3.73.
Revenue of $2,786,000,000 rose by 42.43% from the same period last year, which beat the estimate of $2,730,000,000.
Looking Ahead
The upcoming fiscal year's EPS expected to be between $9.00 and $10.00.
The upcoming fiscal year's revenue expected to be between $8,800,000,000 and $9,100,000,000.
How To Listen To The Conference Call
Date: Oct 22, 2020
Time: 08:30 AM
Price Action
Company's 52-week high was at $131.81
52-week low: $73.02
Price action over last quarter: Up 0.73%
Company Description
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of 2,000 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
